Nama's AI scorecard currently rates Legend Biotech Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does LEGN report earnings?

Legend Biotech's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.01.

What is the LEGN price target?

The median analyst price target from 13 analysts is $48.00, with a range of $24.00 – $68.00.

Is LEGN Shariah compliant?

Nama's AAOIFI-style screen reads Legend Biotech as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Legend Biotech (LEGN)

Healthcare · Biotechnology · NASDAQ

Legend Biotech (LEGN) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $4.55B and a free-cash-flow yield of -3.0%. Over the most recent reported fiscal year, revenue grew 64.0%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Trailing · -40.9% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-69.7%

How far the last close sits under the highest price of the past five years.

Market cap	$4.55B
Trailing P/E	—
Price / book	7.4
Price / sales	3.6
FCF yield	-3.0%
Dividend yield	—
Gross margin	61.2%
Operating margin	-2.3%
Net margin	-13.3%
Revenue growth (YoY)	+64.0%
Revenue growth (3-yr annual)	+106.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

LEGN earnings

Next report: Nov 10, 2026 (Q3 2026, EPS estimate $0.01). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 11, 2026	$0.32	$0.28	+14.3%	$387.50M
Q4 2025	Mar 10, 2026	-$0.16	$0.19	-184.2%	$306.38M
Q3 2025	Nov 12, 2025	-$0.22	-$0.18	-22.2%	$272.33M
Q2 2025	Aug 11, 2025	-$0.68	-$0.23	-195.7%	$255.10M

LEGN analyst price target

Median target $48.00 from 13 analysts, ranging $24.00 – $68.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live LEGN data on Nama Insights →

LEGN FAQ

Is LEGN a buy?: Nama's AI scorecard currently rates Legend Biotech Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does LEGN report earnings?: Legend Biotech's next scheduled report is on Nov 10, 2026. Analysts expect EPS of $0.01.
What is the LEGN price target?: The median analyst price target from 13 analysts is $48.00, with a range of $24.00 – $68.00.
Is LEGN Shariah compliant?: Nama's AAOIFI-style screen reads Legend Biotech as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.